Short Communication: High Rates of Thymidine Analogue Mutations and Dual-Class Resistance Among HIV-Infected Ugandan Children Failing First-Line Antiretroviral Therapy

2013 ◽  
Vol 29 (6) ◽  
pp. 925-930 ◽  
Author(s):  
Kim C.E. Sigaloff ◽  
Joshua Kayiwa ◽  
Victor Musiime ◽  
Job C.J. Calis ◽  
Elizabeth Kaudha ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Short Communication ◽  
First Line ◽  
Thymidine Analogue ◽  
Dual Class

Short Communication: Three Years Follow-Up of First-Line Antiretroviral Therapy in Cambodia: Negative Impact of Prior Antiretroviral Treatment

2011 ◽  
Vol 27 (6) ◽  
pp. 597-603 ◽  
Author(s):  
Olivier Ségéral ◽  
Setha Limsreng ◽  
Janin Nouhin ◽  
ChanRoeurn Hak ◽  
Sopheak Ngin ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Antiretroviral Treatment ◽  
Short Communication ◽  
Negative Impact ◽  
First Line

scholarly journals High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia

Viruses ◽  
2018 ◽  
Vol 10 (2) ◽  
pp. 60 ◽  
Author(s):  
Birkneh Tadesse ◽  
Natalie Kinloch ◽  
Bemuluyigza Baraki ◽  
Hope Lapointe ◽  
Kyle Cobarrubias ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Southern Ethiopia ◽  
First Line ◽  
Dual Class

scholarly journals Cost‐Effectiveness of Tenofovir as First‐Line Antiretroviral Therapy in India

2010 ◽  
Vol 50 (3) ◽  
pp. 416-425 ◽  
Author(s):  
Melissa A. Bender ◽  
Nagalingeswaran Kumarasamy ◽  
Kenneth H. Mayer ◽  
Bingxia Wang ◽  
Rochelle P. Walensky ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Antiretroviral Therapy ◽  
First Line

scholarly journals 1036. Persistence of Guideline-Recommended Antiretroviral Therapy Regimens among Persons Living with HIV Newly Initiating Treatment in the US

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S548-S549
Author(s):  
Joshua P Cohen ◽  
Xingzhi Wang ◽  
Rolin L Wade ◽  
Helena Diaz Cuervo ◽  
Dionne M Dionne
Keyword(s):  
Antiretroviral Therapy ◽  
Proportional Hazards ◽  
Cox Proportional Hazards ◽  
Treatment Discontinuation ◽  
Forest Plot ◽  
Current Guideline ◽  
First Line ◽  
Persons Living With Hiv ◽  
Living With Hiv

Abstract Background Discontinuation of first-line antiretroviral therapy (ART) may lead to poor outcomes for persons living with HIV (PLWH). While single-tablet regimens (STRs) have been associated with greater persistence compared to multi-tablet regimens (MTRs), few real-world studies have assessed persistence with current guideline-recommended ART regimens. The study aims to assess persistence among treatment-naïve PLWH initiating guideline-recommended ART regimens Methods Longitudinal pharmacy claims were extracted from IQVIA’s US LRx database for PLWH initiating ART between Jan 1, 2016 - Jul 31, 2019 (index period), with the observational period up to Jan 31, 2020. Index date was defined as the date of the first ART claim for STRs, or the date of the last filled drug of 1st set of claims for MTRs. Persistence was measured as the number of days until treatment discontinuation (≥ 90-day gap in therapy) and presented via Kaplan-Meier curves. Risk of discontinuation was assessed via Cox proportional hazards models, with BIC/FTC/TAF used as the reference ART regimen. Results Overall, 90,949 PLWH initiated STRs and 20,737 initiated MTRs. Average (SD) age was 43 (14) years, 75% were male, and 75% had commercial insurance. At 6 months of follow-up, 71% of PLWH initiating STRs and 56% initiating MTRs remained on their ART regimen. The proportion remaining on their index regimen at 6 months of follow-up was 79% for BIC/FTC/TAF, 73% for EVG/COBI/FTC/TAF, 71% for DTG/ABC/3TC, 69% for DTG + FTC/TAF, 67% for EFV/FTC/TDF, 62% for EVG/COBI/FTC/TDF, and 38% for DTG + FTC/TDF. Risk of discontinuation was higher for MTRs compared to STRs (hazard ratio [HR]: 1.63, 95% CI: 1.61 - 1.66). Compared to the referent BIC/FTC/TAF, risk of discontinuation was higher for EVG/COBI/FTC/TAF (HR: 1.54, 95% CI: 1.48 - 1.60), DTG/ABC/3TC (HR: 1.58, 95% CI: 1.52, 1.65), DTG + FTC/TAF (HR: 1.83, 95% CI: 1.74 - 1.93), EFV/FTC/TDF (HR: 2.31, 95% CI: 2.21 - 2.41), EVG/COBI/FTC/TDF (HR: 2.58, 95% CI: 2.47 - 2.70), and DTG + FTC/TDF (HR: 6.20, 95% CI: 5.83 - 6.59). Table 1. Persistence with ART by regimen for STR and MTR Figure 1. Forest Plot of Hazard Ratios for Treatment Discontinuation Conclusion Among US adult PLWH, STRs were associated with longer persistence on first-line therapy compared to MTRs. Among STRs, persistence was highest for BIC/FTC/TAF. Disclosures All Authors: No reported disclosures

Comparing effectiveness of first‐line antiretroviral therapy between peri‐urban and rural clinics in KwaZulu‐Natal, South Africa

HIV Medicine ◽  
2022 ◽  
Author(s):  
Jaysingh Brijkumar ◽  
Johnathan A. Edwards ◽  
Brent A. Johnson ◽  
Claudia Ordonez ◽  
Henry Sunpath ◽  
...  
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
First Line ◽  
Kwazulu Natal ◽  
Rural Clinics
Sign in / Sign up

Export Citation Format

Share Document